EVOK - Evoke Pharma, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.8500
+0.0467 (+5.81%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Previous Close0.8033
Open0.8050
Bid0.0000 x 1100
Ask0.0000 x 1100
Day's Range0.8050 - 0.8600
52 Week Range0.5000 - 3.2600
Volume22,376
Avg. Volume443,940
Market Cap20.497M
Beta (3Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed manufacturing commercial scale batches of its product candidate Gimoti (metoclopramide nasal spray) with its partner Thermo Fisher Scientific, a leading global contract development and manufacturing organization that specializes in the preparation, fill and finish of nasal spray products. Evoke plans to collect Chemistry, Manufacturing and Controls (CMC) data from these registration batches, which were requested in the complete response letter (CRL) from the U.S. Food and Drug Administration (FDA).

  • GlobeNewswire

    Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results

    SOLANA BEACH, Calif., Aug. 08, 2019 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today.

  • GlobeNewswire

    Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted a type A meeting request and meeting package to the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) dated April 1, 2019 regarding Evoke’s New Drug Application (NDA) for Gimoti™ for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. During the meeting, Evoke plans to discuss the Company’s strategy to address these issues as well as any other matters pertaining to the steps required for the resubmission of the Gimoti NDA. “We have been working diligently to prepare the meeting package required at the time a type A meeting request is submitted to FDA.

  • GlobeNewswire

    Evoke Pharma Reports First Quarter 2019 Financial Results

    Projected cash runway extended to first quarter 2020 SOLANA BEACH, Calif., May 08, 2019 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on.

  • GlobeNewswire

    Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its 505(b)(2) New Drug Application (NDA) for Gimoti™ for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. The CRL, which cites fewer issues than the recent multidisciplinary review letter, states that FDA has determined it cannot approve the NDA in its present form and provides recommendations to address the two remaining approvability issues in an NDA resubmission.

  • GlobeNewswire

    Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted its response to the U.S. Food and Drug Administration’s (FDA) multi-disciplinary review (DR) letter that was received on March 1, 2019 in association with the Gimoti 505(b)(2) New Drug Application (NDA). In addition, the Company requested a meeting with the FDA prior to the Prescription Drug User Fee Act (PDUFA) action date of April 1, 2019. The purpose of this meeting is to obtain FDA’s feedback on the Company’s responses.

  • GlobeNewswire

    Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication

    Recently received multi-disciplinary review (DR) letter from U.S. Food and Drug Administration (FDA) for Gimoti™ 505(b)(2) New Drug Application (NDA)April 1, 2019 Prescription.

  • GlobeNewswire

    Evoke Pharma Receives Preliminary FDA Communication on Gimoti™ NDA

    Evoke Pharma, Inc. (EVOK), today announced the receipt of a multi-disciplinary review (DR) letter from the U.S. Food and Drug Administration (FDA) in association with the Gimoti 505(b)(2) New Drug Application (NDA). A DR letter is used by the FDA to convey preliminary thoughts on deficiencies identified during the initial stage of NDA review. Although a DR letter reflects preliminary comments that are subject to change and does not reflect a final FDA decision on the NDA, approval of Gimoti by the PDUFA date of April 1, 2019 is uncertain given the letter.

  • GlobeNewswire

    Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2018 on Wednesday, March 6, 2019, after the market closes. Participants should dial 1-877-407-0789 (United States) or 1-201-689-8562 (International) and mention Evoke Pharma. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.evokepharma.com.

  • GlobeNewswire

    Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced a partnership with Novos Growth Partners (NGP) to commercialize Gimoti™, the Company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. NGP will manage the commercial operations for a dedicated sales team to market Gimoti to gastroenterologists and other targeted health care providers, if approved. NGP will also provide non-dilutive working capital for commercialization costs prior to and following product launch.

  • GlobeNewswire

    Evoke Pharma Reports Third Quarter 2018 Results

    April 1, 2019 PDUFA date for Gimoti™ NDA Cash runway extended through June 2019 SOLANA BEACH, Calif., Nov. 13, 2018 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty.